Aspirin still first-line therapy for unstable angina/NSTEMI

July 17, 2012
Aspirin still first-line therapy for unstable angina/NSTEMI
Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction, and ticagrelor can be used in place of clopidogrel or prasugrel instead of aspirin or as a second antiplatelet agent, according to a report from the American College of Cardiology Foundation/American Heart Association published online July 16 in Circulation.

(HealthDay) -- Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and ticagrelor can be used in place of clopidogrel or prasugrel instead of aspirin or as a second antiplatelet agent, according to a report from the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) published online July 16 in Circulation.

Hani Jneid, M.D., from the Baylor College of Medicine in Houston, and colleagues reviewed recent evidence to provide clinicians with a focused update on current guidelines for the management of patients with /NSTEMI. This report updates the 2007 guideline and replaces the 2011 focused update.

The authors recommend that aspirin still be regarded as the first line of therapy for patients with unstable angina/NSTEMI and should be administered as soon as possible after hospital presentation and maintained indefinitely as long as tolerated. Patients who are unable to take aspirin may receive prasugrel (percutaneous coronary intervention-treated patients), ticagrelor, or clopidogrel. Patients who undergo an invasive procedure and are at medium or high risk should receive dual antiplatelet therapy that includes aspirin and a second . Patients undergoing medical treatment alone should be given aspirin indefinitely and clopidogrel or ticagrelor for up to 12 months.

"The AHA and ACCF constantly update their guidelines so that physicians can provide patients with the most appropriate, aggressive therapy with the goal of improving health and survival," Jneid said in a statement. "While this focused update of the guidelines provides important guidance to clinicians, our recommendations are not substitutes for a physician's own clinical judgments and the tailoring of therapy based on individual variability and a patient's presentation and ."

Several members of the writing committee disclosed financial ties to the pharmaceutical industry.

Explore further: Updated AHA/ACCF guidelines for unstable angina include newest blood-thinning drug

More information: Full Text

Related Stories

Updated AHA/ACCF guidelines for unstable angina include newest blood-thinning drug

July 16, 2012
Ticagrelor, a blood-thinning drug approved by the FDA in 2011, should be considered along with older blood thinners clopidogrel and prasugrel for treating patients who are experiencing chest pain or some heart attacks, according ...

New study suggests potent antiplatelet drug effective with low-dose aspirin

June 27, 2011
When taken with higher doses of aspirin (more than 300 milligrams), the experimental antiplatelet drug ticagrelor was associated with worse outcomes than the standard drug, clopidogrel, but the opposite was true with lower ...

Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks

September 26, 2011
Heart attack patients taking selective serotonin reuptake inhibitors (SSRIs) in combination with antiplatelet therapy -- acetylsalicylic acid (ASA), clopidogrel or both (dual antiplatelet therapy) -- are at higher risk of ...

Recommended for you

Biomechanical mapping method aids development of therapies for damaged heart tissue

January 23, 2018
Researchers have developed a new way to capture the detailed biomechanical properties of heart tissue. The high-resolution optical technique fills an important technology gap necessary to develop and test therapies that might ...

Researchers borrow from AIDS playbook to tackle rheumatic heart disease

January 22, 2018
Billions of US taxpayer dollars have been invested in Africa over the past 15 years to improve care for millions suffering from the HIV/AIDS epidemic; yet health systems on the continent continue to struggle. What if the ...

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.